share_log

Unveiling 26 Analyst Insights On Sarepta Therapeutics

Unveiling 26 Analyst Insights On Sarepta Therapeutics

揭示了26個關於sarepta therapeutics的分析師見解
Benzinga ·  09/06 13:01
Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 26 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中,26位分析師提供了Sarepta Therapeutics(納斯達克股票代碼:SRPT)的評級,顯示了看漲和看跌的觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表總結了他們最近的評估,說明了過去30天不斷變化的情緒,並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $188.31, a high estimate of $235.00, and a low estimate of $128.00. This current average reflects an increase of 7.65% from the previous average price target of $174.92.
分析師爲Sarepta Therapeutics設定了12個月的目標股價,顯示平均目標股價爲188.31美元,最高估計爲235.00美元,低估值爲128.00美元。目前的平均價格比之前的平均目標價174.92美元上漲了7.65%。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析師評級:深度分析
The perception of Sarepta Therapeutics by financial experts is analyzed through...
通過分析師最近的行動,...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論